Skip to content

Conservative Treatment for Atypical Endometrial Hyperplasia and Early Endometrial Cancer

Clinical Study of Conservative Treatment for Atypical Endometrial Hyperplasia and Early Endometrial Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06170684
Enrollment
100
Registered
2023-12-14
Start date
2023-12-31
Completion date
2024-01-31
Last updated
2023-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical Endometrial Hyperplasia and Endometrial Cancer

Brief summary

Exploring the efficacy and pregnancy outcomes of conservative treatment for atypical endometrial hyperplasia and endometrial cancer. Study the factors related to predicting treatment efficacy.

Interventions

None listed

Sponsors

Beijing Obstetrics and Gynecology Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* (1) age ≤ 45 years old, strong desire to preserve reproductive function, and no factors of reproductive dysfunction evaluated before treatment; (2) The pathological type is atypical endometrial hyperplasia or endometrial cancer; (3) Imaging examination confirmed that the tumor was localized to the endometrium; (4) There are follow-up conditions available.

Design outcomes

Primary

MeasureTime frame
Complete remission rate6months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026